■原发性甲状腺鳞状细胞癌(PSCCT)是一种罕见的恶性肿瘤。PSCCT的发生率小于1%。然而,PSCCT的诊断和治疗是有限的。手术切除被认为是少数有效的干预方法之一。在这篇文章中,我们报道了1例服用酪氨酸激酶抑制剂(TKIs)联合免疫检查点抑制剂(ICIs)治疗PSCCT的病例.
一名80岁男性因呼吸困难入院,咳嗽,喘息,巨大的甲状腺肿块的声音嘶哑。他接受了支气管镜检查和气管支架植入以减轻呼吸阻塞。然后接受右侧部分甲状腺和右侧淋巴结活检。术后病理提示鳞状细胞癌。随后,他接受了内镜检查以排除上消化道鳞状细胞癌。最后,他被诊断为PSCCT。患者暂时接受安洛替尼和Sindilimab的联合治疗。经过两门课程,5个疗程的联合治疗后,MRI图像中的肿瘤体积显着减小,并且进一步缩小。不幸的是,患者在治疗5个月后死于暴发性肝衰竭和自身免疫性肝病.
■TKIs联合ICIs可能是PSCCT治疗的一种有效和新颖的方法,但是免疫相关的并发症,尤其是肝损伤,应该被关心。
UNASSIGNED: Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant tumor. The incidence rate of PSCCT is less than 1%. However, the diagnosis and treatment of PSCCT are limited. Surgical resection is considered to be one of the few effective intervention methods. In this article, we reported a
case of taking tyrosine kinase inhibitors (TKIs) combined with immune checkpoint inhibitors (ICIs) for PSCCT.
UNASSIGNED: An 80-year-old male was admitted to our hospital with dyspnea, cough, wheezing, and hoarseness for a giant thyroid mass. He underwent bronchoscopy and tracheal stent implantation to alleviate the respiratory obstruction. Then he accepted right partial thyroid and right lymph node biopsy. Postoperative pathology revealed squamous cell carcinoma. Subsequently, he underwent an endoscopy to exclude upper gastrointestinal squamous cell carcinoma. Finally, he was diagnosed with PSCCT. The patient was tentatively treated with a combination of Anlotinib and Sintilimab. After two courses, the tumor volume significantly reduced in MRI images and shrank further after five courses of combined treatment. Unfortunately, the patient died of fulminant liver failure and autoimmune liver disease after 5-month-treatment.
UNASSIGNED: TKIs combined with ICIs may be an effective and novel way for PSCCT treatment, but immune-related complications, especially liver damage, should be cared.